Venetoclax + azacitidine

Venetoclax + azacitidine has been studied in 3 papers since 2026: 1 observational study in people; 3 in the past year. The newest story, Oct 29, 2026: “Stem-cell mutations predicted blood cancer relapse after transplant”.

Intervention

3 papers study it3 more mention it4 findingsUpdated Oct 29, 2026

PubChem PubChem ChEBI ChEBI

2 new papers in 30 daysSee all 6

“Venetoclax/azacytidine depleted detectable MDS HSCs in longitudinally evaluated patients.”

Persistent Malignant Stem Cells Drive Relapse After Transplantation in the Myelodysplastic NeoplasmsbioRxiv2026doi:10.64898/2026.10.28.761431

None of its findings points the other way.

3 independent labs in 3 countries

Funders: Henry and Marilyn Taub Foundation and 5 more

Humans1

What did studies of Venetoclax + azacitidine find?

Studies of Venetoclax + azacitidine measured 4 outcomes; the most studied are detectable MDS hematopoietic stem cells (1 study), therapy-related acute myeloid leukemia (1) and transfusion-dependent cytopenias (1).

Detectable MDS hematopoietic stem cells

downin humans1

1 study

Venetoclax + azacitidine is linked with lower detectable MDS hematopoietic stem cells in humans (patients with myelodysplastic neoplasms evaluated longitudinally).
“Venetoclax/azacytidine depleted detectable MDS HSCs in longitudinally evaluated patients.”
Humanspatients with myelodysplastic neoplasms evaluated longitudinallyhematopoietic stem cell
Stem-cell mutations predicted blood cancer relapse after transplant
bioRxivOct 29, 2026Preprint

More on Detectable MDS hematopoietic stem cells

Therapy-related acute myeloid leukemia

downin humans1

1 study

Venetoclax + azacitidine is linked with lower therapy-related acute myeloid leukemia in humans after CAR-T-associated therapy-related AML (partial remission).
“The patient received azacitidine plus venetoclax, achieving partial remission”
Humansafter CAR-T-associated therapy-related AMLmales
Therapy-related acute myeloid leukemia with 24-month latency after CD19 CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma: a case report
Frontiers in medicineAug 14, 2026

More on Therapy-related acute myeloid leukemia

Transfusion-dependent cytopenias

upin humans1

1 study

Venetoclax + azacitidine is linked with transfusion-dependent cytopenias in humans during the fourth treatment cycle.
“treatment-related transfusion-dependent cytopenias, prompting dose reduction”
Humansduring the fourth treatment cyclefemales
Isolated Neutropenia as a Sentinel of High-Risk Clonal Evolution: Acute Myeloid Leukemia With Myelodysplasia-Related Changes Harboring TP53 Deletion via Isochromosome 17q and Deletion 20q Mimicking a Myeloproliferative Neoplasm
Journal of medical casesApr 29, 2026

Bone marrow blasts

downin humans1

1 study

Venetoclax + azacitidine is linked with lower bone marrow blasts in humans after azacitidine and venetoclax treatment (from above 40% myeloblasts to 8% blasts at day 28).
“Day 28 marrow showed minimal residual disease (blast 8%)”
Humansafter azacitidine and venetoclax treatmentbone marrowday 28females
Isolated Neutropenia as a Sentinel of High-Risk Clonal Evolution: Acute Myeloid Leukemia With Myelodysplasia-Related Changes Harboring TP53 Deletion via Isochromosome 17q and Deletion 20q Mimicking a Myeloproliferative Neoplasm
Journal of medical casesApr 29, 2026

Latest

4 papers in 12 months

bioRxivOct 29

Stem-cell mutations predicted blood cancer relapse after transplant

Relapse was reported in 95.7% of patients with detected stem-cell mutations versus 30.3% without them in an observational cohort after transplantation.Relapse was reported in 95.7% of patients with detected stem-cell mutations versus 30.3% without them in an observational cohort after transplantation.

Preprint: cohort studyBiomarkers